Literature DB >> 26369841

Chronic pain management in dermatology: pharmacotherapy and therapeutic monitoring with opioid analgesia.

Monica Enamandram1, James P Rathmell2, Alexandra B Kimball3.   

Abstract

A number of chronic dermatologic conditions may necessitate long-term adjunctive pain management in addition to treatment of the primary skin disease, such as hidradenitis suppurativa, lichen planus, and other systemic diseases associated with significant pain. Adequate management of chronic pain can represent a unique challenge, but remains an integral component of clinical treatment in relevant contexts. For nociceptive pain of moderate to severe intensity, opioid analgesics can be beneficial when other pain management strategies have failed to produce adequate relief. The decision to initiate long-term opioid therapy must be carefully weighed, and individualized treatment plans are often necessary to effectively treat pain while minimizing adverse effects. Part II of this 2-part continuing medical education article will describe the appropriate settings for initiation of opioid analgesia for dermatology patients and detail therapeutic strategies and patient monitoring guidelines.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  nonsteroidal antiinflammatory drugs; opioid analgesia; pain; postherpetic neuralgia

Mesh:

Substances:

Year:  2015        PMID: 26369841     DOI: 10.1016/j.jaad.2014.11.038

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.

Authors:  Victoria K Shanmugam; Shaunak Mulani; Sean McNish; Sarah Harris; Teresa Buescher; Richard Amdur
Journal:  Int J Dermatol       Date:  2017-11-11       Impact factor: 2.736

Review 2.  Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa [corrected].

Authors:  Zarine S Patel; Lauren K Hoffman; Dawn C Buse; Amy S Grinberg; Ladan Afifi; Steven R Cohen; Michelle A Lowes; Elizabeth K Seng
Journal:  Curr Pain Headache Rep       Date:  2017-11-01

Review 3.  Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.

Authors:  Jia-Jia Zhang; Chang-Geng Song; Ji-Min Dai; Ling Li; Xiang-Min Yang; Zhi-Nan Chen
Journal:  MedComm (2020)       Date:  2022-06-22

Review 4.  Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis.

Authors:  Aikaterini Tsentemeidou; Elena Sotiriou; Nikolaos Sideris; Alexandra Kourouklidou; Aimilios Lallas; Dimitrios Ioannides; Efstratios Vakirlis
Journal:  Dermatol Pract Concept       Date:  2022-04-01

Review 5.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

Review 6.  Is substance use disorder more prevalent in patients with hidradenitis suppurativa?

Authors:  Paola C Aldana; Marcia S Driscoll
Journal:  Int J Womens Dermatol       Date:  2019-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.